Encourage international talent to support cancer research
To keep discovering new cancer tests and treatments, we need to be able to recruit and retain the best talent and scientific leaders.
Being a global institution is part of what makes us successful and international talent is a key part of our research workforce. More than 35 per cent of our staff are from outside of the UK and we have staff from 67 different countries.
Recent modelling by the Royal Society showed that total upfront visa costs are up to seventeen times higher in the UK compared to the international average. It is simply not sustainable to have barriers of this magnitude in the way of attracting the best global talent when we are competing with the leading universities, institutes and companies across Europe and the USA.
Our ask: The UK needs a visa and immigration system which is competitive with other leading research nations. This is essential for us to continue being internationally leading and to compete with institutes and universities across the world. The Government should support the aim of recruiting international talent and leaders by reducing the costs for researchers, so the UK is competitive with comparable nations.
Advocacy blog posts
The Charity Research Support Fund: An overlooked, and neglected, lifeline for UK science
Ollie Richards, Advocacy Manager at the ICR, explores how a critical element of the Government's research funding – the Charity Research Support Fund – could be reformed to help support more specialist institutions and universities to do life-saving research.
100 days in – what do we need from the Government to enable cancer research to thrive?
We’re now 100 days into the new Government and the ICR’s Advocacy Manager, Ollie Richards, outlines what academic institutions need the Government to prioritise to help us on our mission to continue making the discoveries that defeat cancer.
Latest ICR News
New clinical trial design could improve dose selection, maximising treatment efficacy and safety
Researchers have developed a new approach to help determine the optimal dose of cancer drugs, aiming to make early-stage clinical trials more transparent and better aligned with patient needs.
The ICR and The Royal Marsden partner with Mint Medical on roll out of global AI cancer imaging tool
The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust have announced a new licensing agreement with MedTech company Mint Medical, a Snke Company, to improve monitoring for patients with bone disease in advanced prostate cancer and multiple myeloma.
Targeting cancer cell DNA repair mechanism may make radiotherapy more effective
Scientists have uncovered a mechanism that helps cancer cells survive radiation, pointing to a potential new way to make treatment more effective.